Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of upadacitinib versus dupilumab in children with moderate to severe atopic dermatitis
CTR20244498Phase 3Active
- Sponsor
- AbbVie Inc.
- Start
- Mar 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of upadacitinib and dupilumab in atopic dermatitis (AD) (3 arms), sponsored by AbbVie Inc. Primary endpoints: Proportion of participants achieving EASI 75, Proportion achieving vIGA-AD 0/1 with at least 2-point improvement and 1 more. Started Mar 2025; status: active.
02
Drugs
upadacitinibdupilumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20244498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244498.